References

1 Brouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L for the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. Can Med Assoc J.  2010. Available online July 5, 2010.  doi:10.1503/cmaj.090449

2 Tran, H. A. (2013). An update of consensus guidelines for warfarin reversal. Med J Aust, 198 (4), 198-199.
 
3 Egea-Guerrerro JJ, Q. D. (2015). New oral anticoagulants in severe trauma patients: Enemy at the gates? Med Intensiva; 39 (3), 167-171.
 
4 Melbourne Health. (2015). Clinician Guidelines: Warfarin Anticoagulation Reversal. Emergency Department. Melbourne: Melbourne Health: Policies, procedures and guidelines.
 
5 Wood, P. (2013). New oral anticoagulants: An emergency department overview.  Emergency medicine Australasia 25, 503-514.
 
6 Wijeyeratne, Y D; Heptinstall, S (2011) Anti-platelet therapy: ADP receptor antagonists. British Journal of Clinical Pharmacology. 72(4): 647-657
 
7 Goel, D. (2013) Ticagrelor: The first approved reversible oral antiplatelet agent. Int J Appl Basic Med Res. 2013 Jan; 3(1):19-21. doi: 10.4103/2229-516X.112234
 
8 Bauer, K. (2013, December 6). Pros and Cons of new anticoagulants. Retrieved from American Society of Hematology, The Education Program: http://asheducationbook.hematologylibrary.org/content/2013/1/464.full?sid=91f73efc-7467-49cb-b1c2-c365e698c482
 
9 Pollack, C.V (2015). Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J, 0; 1-8 25.01.2017 doi:10.1136/emermed-2015-204891.
 
10 Medicines Regulation and Quality, Department of Health, Queensland Government. (2016). Managing Patients on Dabigatran (Pradaxa®) Guidelines. Brisbane: State of Queensland (Queensland Health) July 2016.
 
11 Tuane,V. Wallen, H. Agren, A. Gryfelt, G. Slovik,C, Wintler, AM. Malmstrom, RE Skeppholm, M. Whole blood coagulation assays ROTEM and T-TAS to monitor Dabigatran treatment, Elsevier, Thrombosis research, (2017) 76-82
 
12 Queensland Health. (2012). Rotational thromboelastometry (ROTEM) - targeted therapy for coagulation management in patent’s with massive bleeding. Health Policy Advisory Committee on Technology
 
13 McCoy, C. C. (2014). Management of Anticoagulation Agents in Trauma Patients. Clin Lab Med 34, 563-574.
 
14 Medicines Regulation and Quality, Department of Health, Queensland Government. (2014). Guideline for managing patients on a factor Xa inhibitor – Apixaban (Eliquis®) or Rivaroxaban (Xarelto®). Brisbane: State of Queensland (Queensland Health).
 
15 Spahn, D. B.-M. (2013). Management of bleeding and coagulation following major trauma: an updated European guideline. Critical Care, 17, R76.
 
16 Pollack, C. V. (2015). Idarucizumab for Dabigatran Reversal. N Engl J Med, 373: 511-20 http://doi: 10.1056/NEJMoa1502000.
 
17 Tran, H. Joseph, J. Young, L. McRae, S. Curnow, J, Nandurkar, H. Wood, P. and McLintock, C. New oral anticoagulants: a practical guide on prescription laboratory testing and peri-procedural / bleeding management. Int Med J. 2014;(44):525-36